Chimeric Therapeutics Limited (ASX:CHM)
Australia · Delayed Price · Currency is AUD 0.0030
+0.0010 (50.00%)
Sep 5, 2025, 4:10 PM AEST
Chimeric Therapeutics Revenue
In the fiscal year ending June 30, 2025, Chimeric Therapeutics had annual revenue of 12.68M AUD with 70.09% growth. Chimeric Therapeutics had revenue of 7.13M in the half year ending June 30, 2025, with 376.67% growth.
Revenue
12.68M
Revenue Growth
+70.09%
P/S Ratio
0.77
Revenue / Employee
n/a
Employees
n/a
Market Cap
9.76M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 12.68M | 5.23M | 70.09% |
| Jun 30, 2024 | 7.46M | 2.95M | 65.52% |
| Jun 30, 2023 | 4.51M | 1.89M | 72.16% |
| Jun 30, 2022 | 2.62M | - | - |
| Jun 30, 2021 | - | - | - |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| CSL Limited | 23.73B |
| Pro Medicus | 212.98M |
| Cochlear | 2.34B |
| Sonic Healthcare | 9.65B |
| Ramsay Health Care | 17.79B |
| Ansell | 3.06B |
| Telix Pharmaceuticals | 1.01B |
| Mesoblast | 26.23M |